1. Homepage
  2. Equities
  3. Canada
  4. Bourse de Toronto
  5. MedMira Inc.
  6. Summary
    MIR   CA58501R1029

MEDMIRA INC.

(MIR)
Delayed Bourse de Toronto  -  02:19 2022-08-10 pm EDT
0.1050 CAD   -4.55%
07/15MedMira Strengthens and Expands Board
MT
07/15MedMira Inc. Announces Board Changes
CI
07/14MedMira Strengthens and Expands Board
AQ
 SummaryQuotesChartsNewsCalendarCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Bourse De Toronto
08/04/2022 08/05/2022 08/08/2022 08/09/2022 08/10/2022 Date
0.11(c) 0.115(c) 0.115(c) 0.11(c) 0.105 Last
138 027 25 388 28 500 35 000 75 006 Volume
-8.33% +4.55% 0.00% -4.35% -4.55% Change
More quotes
Estimated financial data (e)
Sales 2020 0,92 M 0,72 M 0,72 M
Net income 2020 -2,05 M -1,60 M -1,60 M
Net Debt 2020 11,5 M 9,02 M 9,02 M
P/E ratio 2020 -135x
Yield 2020 -
Sales 2021 2,14 M 1,68 M 1,68 M
Net income 2021 -0,68 M -0,53 M -0,53 M
Net Debt 2021 11,5 M 9,04 M 9,04 M
P/E ratio 2021 -117x
Yield 2021 -
Capitalization 73,6 M 57,7 M 57,7 M
EV / Sales 2020 313x
EV / Sales 2021 42,4x
Nbr of Employees 52
Free-Float 28,7%
More Financials
Company
MedMira Inc. is a Canada-based biotechnology company. The Company is engaged in the development and commercialization of rapid diagnostics and technology platforms. The MedMira Rapid Vertical Flow (RVF) Technology platform is the basis for the Company's line of rapid tests. Its technology platform detects multiple biomarkers specific to several diseases using a single cartridge. Its Multiplo line of rapid tests for... 
More about the company
All news about MEDMIRA INC.
07/15MedMira Strengthens and Expands Board
MT
07/15MedMira Inc. Announces Board Changes
CI
07/14MedMira Strengthens and Expands Board
AQ
06/29MedMira Reports Third Quarter Results FY2022
AQ
06/29MedMira Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April..
CI
06/06MedMira Receives US Patent for Unique Quantitative Diagnostic System
MT
06/06MedMira Receives Patent for its Unique Quantitative Diagnostic System
AQ
05/27MedMira Provides Update on New In Vitro Diagnostic Medical Devices Regulation (IVDR) in..
MT
05/27MedMira provides an update on the new In Vitro Diagnostic Medical Devices Regulation (I..
AQ
05/27MedMira Inc. Provides an Update on the New in Vitro Diagnostic Medical Devices Regulati..
CI
05/20MedMira Inc. Provides an Update on Regulatory Work for Canada for Its VYRA™ Produc..
CI
05/20VYRA™ Product Line Update
GL
05/13MEDMIRA IRL BRIEF : Q1 Loss Per Share US$0.05, Unchanged From a Year Ago
MT
05/12MedMira Receives CE Mark For Multiplo Antibody Test
MT
05/12MedMira receives CE mark for Multiplo® Complete Syphilis (TP/nTP) Antibody Test
GL
More news
News in other languages on MEDMIRA INC.
07/15MedMira Inc. annonce des changements au conseil d'administration
06/29MedMira Inc. annonce ses résultats pour le troisième trimestre et les neuf mois terminé..
06/06MedMira reçoit un brevet américain pour un système unique de diagnostic quantitatif
05/27MedMira Inc. Fournit une mise à jour sur la nouvelle réglementation des dispositifs méd..
05/20MedMira Inc. Fournit une mise à jour sur les travaux de réglementation au Canada pour s..
More news
Chart MEDMIRA INC.
Duration : Period :
MedMira Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Hermes Hermes Chan President, Chief Executive Officer & Director
Markus M. Meile Chief Financial Officer
Thomas Bergmann Independent Chairman
Pascale Nini Independent Director
Steve Cummings Director
Sector and Competitors
1st jan.Capi. (M$)
MEDMIRA INC.-45.00%60
THERMO FISHER SCIENTIFIC-12.94%227 578
DANAHER CORPORATION-13.30%207 497
INTUITIVE SURGICAL, INC.-35.19%83 164
EDWARDS LIFESCIENCES CORPORATION-21.70%62 887
BOSTON SCIENTIFIC CORPORATION-3.41%58 739